Mission Bio's Tapestri Enables Single-Cell Profiling of Residual Disease, Identifying AML Patients Likely to Benefit from Motixafortide in the Multicenter BLAST Trial

SOUTH SAN FRANCISCO, Calif. & HEIDELBERG, Germany, June 03, 2026--Mission Bio, a leader in single-cell multiomics, jointly ...
Business Insider

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation ...

ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis Transcript

We hope you've had a chance to review the press release we issued after market close in the U.S. today, announcing the positive top-line results of the Phase III ABTECT Maintenance trial. Joining me ...

Enzymes that assemble into droplets can speed up cellular reactions, biologists find

Within the past decade, biologists have discovered that one strategy cells use to keep their contents organized is a ...
Medscape

HCV Antiviral Moves Toward EU Use in Acute Infection

European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.

Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at ...

Data for patients treated at or below recommended Phase 2 dose (RP2D) showed 84.6% disease control rate (33/39), including 3 partial responses (2 ...

Novel combination therapy could reduce leukemia relapse rate, extending window for bone marrow transplants

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong ...
TMCnet

Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the ...

REM-422 is the first oral mRNA degrader of MYB demonstrating proof-of-concept in ACC. In this study, pharmacokinetic and pharmacodynamic analyses conirmed robust compound exposure in blood and target ...
Nature

Acute Phase Protein Dynamics in Equine Health

The acute phase response in horses is a rapid, systemic reaction to tissue injury, infection, exercise or stress, characterised by changes in the concentrations of specific plasma proteins. Key acute ...
Business Wire

Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases

TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, today announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound developed to ...
Reuters

Gulf crisis moves from acute to chronic phase

NEW YORK, April 17 (Reuters Breakingviews) - The Gulf energy crisis isn’t over. Ever since the United States and Israel launched joint strikes on Iran, regional tumult has throttled worldwide oil and ...
Frontiers

Protein nutritional support in critically ill patients: pathophysiological basis, clinical evidence, and areas of uncertainty – a narrative review

Protein metabolic derangement is a hallmark of critical illness and contributes to adverse outcomes and delayed recovery. This narrative review synthesises current evidence on protein metabolism, ...